Resistance mechanisms in KRAS-G12C-mutated cancer

被引：0
|
作者：
Gassa, Asmae [1 ]
Ozkan, Filiz [2 ,3 ]
Ast, David [4 ]
Wahlers, Thorsten [1 ]
Bruns, Christiane [5 ]
Alakus, Hakan [5 ]
机构：
[1] Univ Klinikum Koln AoR, Klin & Poliklin Herzchirurg Herzchirurg Intens Me, Kerpener Str 62, D-50937 Cologne, Germany
[2] Univ Med Mannheim, Sekt Pneumol, Med Klin 1, Mannheim, Germany
[3] Ohio State Univ, James Comprehens Canc Ctr, Columbus, OH 43210 USA
[4] Univ Cologne, Inst Pathol, Univ Klinikum Koln AoR, Mol,Pathol, Cologne, Germany
[5] Univ Klinikum Koln AoR, Klin & Poliklin Allgemein Viszeral & Tumorchirug, Cologne, Germany
来源：
ONKOLOGE | 2021年 / 27卷 / 12期
关键词：
D O I：
10.1007/s00761-021-01038-y
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1243 / 1244
页数：2
相关论文
共 50 条
  • [21] AXL activation promotes adaptive resistance to KRAS-G12C inhibitors in KRASG12C-mutated non-small cell lung cancer
    Morimoto, Kenji
    Yamada, Tadaaki
    Hirai, Soichi
    Katayama, Yuki
    Kunimasa, Kei
    Sasaki, Takaaki
    Nishida, Makoto
    Watanabe, Satoshi
    Shiotsu, Shinsuke
    Uehara, Hisanori
    Takayama, Koichi
    CANCER RESEARCH, 2024, 84 (06)
  • [22] Anti-KRAS G12C and Anti-EGFR Rechallenge in Chemotherapy-Refractory KRAS G12C-Mutated Colorectal Cancer: A Case Report
    Morris, Linda
    Pappas, Leontios
    Pandey, Aditya
    Singh, Harshabad
    Klempner, Samuel
    Caughey, Bennett
    JCO PRECISION ONCOLOGY, 2024, 8
  • [23] Adagrasib plus cetuximab - a novel therapy in the KRAS G12C mutated colorectal cancer treatment
    Khan, Ayesha
    Chawla, Sakshi
    Hussain, Tooba
    Haque, Md Ariful
    ANNALS OF MEDICINE AND SURGERY, 2025, 87 (01): : 11 - 12
  • [24] The KRAS-G12C inhibitor: activity and resistance
    Jiao Liu
    Rui Kang
    Daolin Tang
    Cancer Gene Therapy, 2022, 29 : 875 - 878
  • [25] Characterizing the clinico-genomic landscape and outcomes of KRAS G12C mutated pancreas cancer
    Keane, F.
    Park, W.
    Varghese, A.
    Balogun, F.
    Yu, K.
    El Dika, I.
    Khalil, D.
    Kelsen, D. P.
    Reidy-Lagunes, D.
    Ku, G. Y.
    Raj, N.
    Chou, J. F.
    Capanu, M.
    Schultz, N.
    Yaeger, R.
    O'Reilly, E.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1140 - S1140
  • [26] The KRAS-G12C inhibitor: activity and resistance
    Liu, Jiao
    Kang, Rui
    Tang, Daolin
    CANCER GENE THERAPY, 2022, 29 (07) : 875 - 878
  • [27] D-1553 in patients with KRAS G12C mutated advanced pancreatic cancer (pca)
    Kondo, S.
    Yan, D.
    Ganju, V.
    Richardson, G.
    Hou, X.
    Shan, J.
    Liu, X.
    Zhang, Y.
    Xie, X.
    Xiang, Z.
    Shi, Z.
    Wang, Y.
    Zhang, L.
    Yamamoto, N.
    ANNALS OF ONCOLOGY, 2023, 34 : S898 - S899
  • [28] Identification of intrinsic resistance mechanisms to KRAS-G12C inhibitor using patient derived colorectal cancer cells
    Maruyama, Kohei
    Shimizu, Yuki
    Suzuki, Mai
    Ohhara, Tomoko
    Fujita, Naoya
    Nagayama, Satoshi
    Katayama, Ryohei
    CANCER SCIENCE, 2022, 113
  • [29] Elucidating the mechanisms of acquired resistance to AMG510 in cancer models harboring KRAS G12C mutations
    Ni, Ting
    Huo, Tongxin
    Zhang, Yawen
    Wang, Jingjing
    Liu, Gaoxiang
    Shi, Wenting
    Gu, Qingyang
    CANCER RESEARCH, 2024, 84 (06)
  • [30] Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC
    Cheema, Parneet K.
    Banerji, Shantanu O.
    Blais, Normand
    Chu, Quincy S. C.
    Juergens, Rosalyn A.
    Leighl, Natasha B.
    Sacher, Adrian
    Sheffield, Brandon S.
    Snow, Stephanie
    Vincent, Mark
    Wheatley-Price, Paul F.
    Yip, Stephen
    Melosky, Barbara L.
    CURRENT ONCOLOGY, 2023, 30 (07) : 6473 - 6496
12345